36 Supported by research
Scientific data demonstrates that social isolation is an independent risk factor for neurodegenerative disease, cardiovascular disease, and cancer.
"There's so much data to show that that social isolation is a risk factor for neurodegenerative and cardiovascular and even cancer." (said at 0:00:27)
Large-scale prospective cohort studies and meta-analyses support the claim that social isolation is an independent risk factor associated with increased risks of neurodegenerative disease (such as dementia), cardiovascular disease, and cancer mortality. A 2023 meta-analysis of 90 prospective cohort studies comprising over 2.2 million individuals found that social isolation was significantly associated with elevated risks of cardiovascular disease mortality (pooled effect size 1.34) and cancer mortality (pooled effect size 1.24). Furthermore, a prospective cohort study of 462,619 UK Biobank participants demonstrated that social isolation independently increased the risk of incident all-cause dementia by 26% (hazard ratio 1.26) after adjusting for extensive demographic, biological, and socioeconomic covariates.
- supports: Associations of Social Isolation and Loneliness With Later Dementia. (Neurology 2022) · cited 253x in the literature
"Social isolation was associated with a 1.26-fold increased risk of dementia (95% CI, 1.15-1.37) independently of various risk factors including loneliness and depression (i.e., full adjustment)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: A systematic review and meta-analysis of 90 cohort studies of social isolation, loneliness… (Nature human behaviour 2023) · cited 437x in the literature
"Here we show that, in the general population, both social isolation and loneliness were significantly associated with an increased risk of all-cause mortality (pooled effect size for social isolation, 1.32; 95% confidence interval (CI), 1.26 to 1.39; P < 0.001) and cancer mortality (pooled effect size for social isolation, 1.24; 95% CI, 1.19 to 1.28; P < 0.001; pooled effect size for loneliness, 1.09; 95% CI, 1.01 to 1.17; P = 0.030). Social isolation also increased the risk of CVD mortality (1.34; 95% CI, 1.25 to 1.44; P < 0.001)." (abstract, results, passage verified)
pubmedfull study (doi)
Whole-genome sequencing of 1,400 individuals in the Welderly study (average age near 90 with no chronic illnesses) revealed almost no common protective genetic underpinnings.
"So it was called the Welderly study and it took seven years to find 1,400 people who were average age near 90 and up to 102 who had never had a chronic illness uh age-related or otherwise... we did whole genome sequencing on all of them and surprisingly we thought we'd find as you said all these genetic underpinnings and we found almost nothing." (said at 0:03:04)
Whole-genome sequencing of the Welderly cohort (healthy elderly individuals aged 80 and older who had never developed chronic diseases) demonstrated that healthy aging was not driven by distinct common longevity variants or an absence of rare pathogenic variants. While the investigators found modest reductions in polygenic susceptibility to Alzheimer's disease and coronary artery disease alongside suggestive loci related to cognitive preservation, the sequencing did not uncover definitive master protective genetic variants explaining their exceptional disease-free survival.
- supports: Whole-Genome Sequencing of a Healthy Aging Cohort. (Cell 2016) · cited 250x in the literature
"In contrast with studies of exceptional longevity, usually focused on centenarians, healthy aging is not associated with known longevity variants, but is associated with reduced genetic susceptibility to Alzheimer and coronary artery disease. Additionally, healthy aging is not associated with a decreased rate of rare pathogenic variants, potentially indicating the presence of disease-resistance factors." (abstract, results, passage verified)
pubmedfull study (doi)
Multiple studies show that high polygenic disease risk can be neutralized by adopting healthy lifestyle factors.
"there are several studies I review in the book of polygenic risk uh and how that's neutralized by lifestyle factors." (said at 0:05:07)
Multiple large prospective cohort studies demonstrate that adhering to a healthy lifestyle (such as not smoking, regular physical activity, a healthy diet, and maintaining a healthy body weight) substantially offsets or attenuates the elevated risk conferred by high polygenic risk scores across multiple conditions, including coronary artery disease, stroke, and dementia. For example, a landmark study of over 55,000 participants published in The New England Journal of Medicine found that a favorable lifestyle was associated with a ~46–50% lower relative risk of coronary events among individuals in the highest quintile of genetic risk. Similar independent protective associations have been demonstrated for dementia and stroke in the UK Biobank. Under GRADE criteria, certainty is graded as low because the underlying evidence is observational.
- supports: Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. (The New England journal of medicine 2016) · cited 1507x in the literature
"Among participants at high genetic risk, a favorable lifestyle was associated with a 46% lower relative risk of coronary events than an unfavorable lifestyle (hazard ratio, 0.54; 95% CI, 0.47 to 0.63). This finding corresponded to a reduction in the standardized 10-year incidence of coronary events from 10.7% for an unfavorable lifestyle to 5.1% for a favorable lifestyle in ARIC, from 4.6% to 2.0% in WGHS, and from 8.2% to 5.3% in MDCS." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Association of Lifestyle and Genetic Risk With Incidence of Dementia. (JAMA 2019) · cited 916x in the literature
"Among participants with high genetic risk, 1.13% (95% CI, 1.01%-1.26%) of those with a favorable lifestyle developed dementia compared with 1.78% (95% CI, 1.38%-2.28%) with an unfavorable lifestyle (hazard ratio, 0.68 [95% CI, 0.51-0.90])." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Healthy lifestyles are associated with alleviating the single-nucleotide polymorphism-base… (Stroke and vascular neurology 2025) · cited 2x in the literature
"Healthy lifestyles were substantially associated with a reduction in the risk of IS, ICH and MI and attenuated the genetic risk of IS, ICH and MI by at least half, respectively." (abstract, conclusions, passage verified)
pubmedfull study (doi)
Proteomic analysis using up to 11,000 plasma proteins can determine eight distinct organ aging clocks, including brain, heart, liver, kidney, and immune system.
"these protein or proteomic scores where you take up to 11,000 plasma proteins and you get eight organ clocks including the immune system. So brain, heart, liver, kidney." (said at 0:07:40)
Large-scale plasma proteomic studies using high-throughput platforms (such as SomaScan assays measuring thousands of plasma proteins, up to 11,000 targets) have developed and validated organ-specific proteomic biological aging clocks. These models assess distinct biological age gaps across major organs and systems, including the brain, heart, liver, kidney, and immune system, and have demonstrated predictive validity for organ-specific disease onset and mortality in large human cohorts.
- supports: Organ aging signatures in the plasma proteome track health and disease. (Nature 2023) · cited 615x in the literature
"We utilized levels of human blood plasma proteins originating from specific organs to measure organ-specific aging differences in living individuals. Using machine learning models, we analysed aging in 11 major organs and estimated organ age reproducibly in five independent cohorts encompassing 5,676 adults across the human lifespan." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Proteomic organ-specific ageing signatures and 20-year risk of age-related diseases: the W… (The Lancet. Digital health 2025) · cited 52x in the literature
"Age gaps of nine organs were determined from plasma proteins via SomaScan (SomaLogic; Boulder, CO, USA) using the Python package organage... 2·03 (1·51-2·74) for the arterial age gap, 1·78 (1·48-2·14) for the kidney age gap, 1·52 (1·38-1·68) for the heart age gap, 1·52 (1·12-2·06) for the brain age gap, 1·43 (1·16-1·78) for the pancreas age gap, 1·37 (1·17-1·61) for the lung age gap, 1·36 (1·26-1·46) for the immune system age gap, and 1·30 (1·18-1·42) for the liver age gap." (abstract, results)
pubmedfull study (doi)
The UK Biobank is measuring proteomic profiles across 500,000 participants at a cost of approximately $50 per person, having already profiled over 50,000 individuals.
"and the biobank, UK Biobank is doing it for $50 for in 500,000 people. They've already done it in 50-some thousand." (said at 0:08:10)
The published record confirms that the UK Biobank Pharma Proteomics Project characterized plasma proteomic profiles for an initial phase of 54,219 participants ("50-some thousand"), as part of ongoing efforts to scale proteomic profiling across the broader UK Biobank cohort of 500,000 individuals.
Cardiovascular disease is 80% to 90% preventable through lifestyle, while cancer and neurodegenerative diseases are 40% to 50% preventable through lifestyle.
"cardiovascular is the most preventable of these three diseases. Um, 80 90%. Uh, our colleagues, uh, former colleagues from Cleveland Clinic came out with that's 90%, others 80%. But then cancer and neurodegenerative are 40 50% preventable through lifestyle." (said at 0:11:48)
Large-scale epidemiological studies and major consensus reports support these estimates. In cardiovascular disease, the landmark global INTERHEART study found that nine modifiable lifestyle and cardiometabolic risk factors accounted for 90% of the population attributable risk of myocardial infarction in men and 94% in women, with other major cardiovascular bodies commonly citing 80% to 90% preventability. For cancer, epidemiological analyses consistently estimate that 40% to 50% of incident cancer cases are attributable to modifiable lifestyle and environmental risk factors (such as tobacco use, diet, excess weight, alcohol, and physical inactivity). Similarly, major consensus bodies such as the Lancet Commission on dementia estimate that approximately 40% to 45% of dementia cases worldwide are attributable to modifiable lifestyle and health risk factors across the lifespan.
The Alzheimer's Association diagnostic criteria categorize individuals with elevated plasma p-tau217 as having stage 1 Alzheimer's disease.
"And the American Alzheimer's Association, which I think has some problems, they're labeling people with p-tau217 as stage one Alzheimer's if it's elevated." (said at 0:28:55)
The revised criteria from the Alzheimer's Association Workgroup (Jack et al., 2024) establish a biological definition of Alzheimer's disease (AD) wherein disease onset occurs while individuals are asymptomatic. Under this framework, Core 1 biomarkers—specifically including accurate plasma biomarkers such as phosphorylated tau 217 (p-tau217)—are sufficient to establish a biological diagnosis of AD. Under the clinical staging framework, individuals who test positive for AD biomarkers but remain asymptomatic/cognitively unimpaired are categorized as having Stage 1 Alzheimer's disease.
The development of the three major categories of age-related diseases—most cancers, cardiovascular disease, and neurodegenerative disease—takes more than 20 years before clinical manifestation.
"The three major age-related diseases uh take more than 20 years. Uh cancer for almost all cancers, uh cardiovascular and certainly Alzheimer's neurodegenerative they take more than 20 years" (said at 0:10:12)
Scientific consensus across geroscience, oncology, cardiology, and neurology confirms that the preclinical development of the major chronic age-related diseases typically spans decades before clinical diagnosis. For neurodegenerative diseases such as Alzheimer's disease, biomarker and neuropathological studies demonstrate that pathological cascades (including amyloid-beta deposition and tau pathology) begin 20 or more years prior to symptom onset. Similarly, cardiovascular disease develops via atherosclerosis beginning in early life as fatty streaks that evolve over decades before resulting in acute events, and genomic/evolutionary modeling of common adult solid cancers indicates that initial driver mutations often precede clinical tumor manifestation by 15 to 30 years.
Researchers are actively using gene editing techniques to convert the APOE4 allele into APOE2 in animal models.
"there's a whole chapter in the book where people are editing APO turning APOE4 into APOE2 right now. I mean, ... In animals and you know, the idea of to do this in people that may happen someday" (said at 0:18:28)
Preclinical researchers are actively investigating genetic and gene-editing strategies to convert the high-risk APOE4 allele into protective or lower-risk variants such as APOE2 and APOE3 in animal models. For example, mouse models engineered for inducible allelic switching from APOE4 to APOE2 have demonstrated improvements in cerebral lipid profiles, reduction of amyloid pathology, and reversal of cognitive deficits. Additionally, CRISPR- and prime-editing platforms are being actively tested in vivo in humanized APOE4 mouse models to convert APOE4 toward lower-risk alleles.
- supports: APOE4 to APOE2 allelic switching in mice improves Alzheimer's disease-related metabolic si… (Nature neuroscience 2025) · cited 14x in the literature
"Here we develop a knock-in model that allows for an inducible 'switch' between risk and protective alleles (APOE4s2)... Finally, when crossed to the 5xFAD background, astrocyte-specific E4 to E2 switching improves cognition, decreases amyloid pathology, lowers gliosis and reduces plaque-associated apolipoprotein E." (abstract, results)
pubmedfull study (doi) - supports: CRISPR-based correction of apolipoprotein E4 in Alzheimer's disease: Therapeutic strategie… (International journal of biological macromolecules 2026) · cited 1x in the literature
"CRISPR-based genome editing technologies, including nuclease disruption, base editing, and prime editing, offer unprecedented opportunities to directly modify APOE4 at its genomic source. Here, we review mechanistic underpinnings of APOE4 pathology, summarize current gene editing platforms for APOE4 correction, evaluate relevant in vitro and in vivo model systems" (abstract, results, passage verified)
pubmedfull study (doi)
Daily protein intake beyond 1.5 to 1.6 grams per kilogram of body weight does not yield additional increases in muscle mass in clinical studies.
"And it's not going to increase their muscle mass when you go past good studies, 1.5, 1.6 per kilogram." (said at 0:33:05)
A landmark systematic review, meta-analysis, and meta-regression of 49 randomized controlled trials with 1,863 participants undergoing resistance exercise training found that dietary protein supplementation enhanced gains in fat-free mass up to a plateau. Two-phase breakpoint analysis demonstrated that protein intakes exceeding approximately 1.62 g/kg/day provided no further resistance training-induced gains in fat-free mass or muscle size.
In a 30-year follow-up study of 105,000 people, only 9% reached elderly age past 70 in healthy status, and those 9% predominantly consumed plant-based foods, a Mediterranean diet, and small amounts of red meat.
"And you're familiar with this recent study of 105,000 people followed 30 years, and only 9% of them only 9% got to the elderly state past age 70. And those 9%, what did they eat? They mainly ate plant-based foods, Mediterranean diet, some but small amounts of red meat" (said at 0:33:40)
A 2025 prospective cohort study published in Nature Medicine analyzed 105,015 participants from the Nurses' Health Study and the Health Professionals Follow-Up Study followed for up to 30 years (1986–2016). The researchers found that only 9,771 participants (9.3%) achieved healthy aging, defined as surviving to age 70 or older free of major chronic diseases and with intact cognitive, physical, and mental function. Greater adherence to healthy dietary patterns (including the Mediterranean diet, Alternative Healthy Eating Index, and healthful plant-based diets rich in fruits, vegetables, whole grains, nuts, legumes, and unsaturated fats, alongside minimal intake of red and processed meats) was significantly associated with achieving healthy aging.
- supports: Optimal dietary patterns for healthy aging. (Nature medicine 2025) · cited 196x in the literature
"Here, using longitudinal questionnaire data from the Nurses' Health Study (1986-2016) and the Health Professionals Follow-Up Study (1986-2016), we examined the association of long-term adherence to eight dietary patterns and ultraprocessed food consumption with healthy aging, as assessed according to measures of cognitive, physical and mental health, as well as living to 70 years of age free of chronic diseases. After up to 30 years of follow-up, 9,771 (9.3%) of 105,015 participants (66% women, mean age = 53 years (s.d. = 8)) achieved healthy aging... Higher intakes of fruits, vegetables, whole grains, unsaturated fats, nuts, legumes and low-fat dairy products were linked to greater odds of healthy aging, whereas higher intakes of trans fats, sodium, sugary beverages and red or processed meats (or both) were inversely associated." (abstract, results, passage verified)
pubmedfull study (doi)
Slow-wave deep sleep is the specific sleep stage during which the brain clears toxic waste metabolites.
"the link between the deep sleep, which is when we get rid of the toxic waste metabolites in our brain, that's the time." (said at 0:39:20)
Mechanistic animal and human physiological studies demonstrate that sleep—particularly non-rapid eye movement (NREM) slow-wave deep sleep—substantially enhances the clearance of toxic metabolic waste products (such as amyloid-beta and tau) from the central nervous system via the glymphatic system. Preclinical work showed a dramatic expansion of the interstitial space and increased convective cerebrospinal fluid (CSF)-interstitial fluid exchange during sleep, and human neuroimaging confirmed that electrophysiological slow waves in NREM sleep drive large coupled waves of CSF flow responsible for waste clearance.
- supports: Sleep drives metabolite clearance from the adult brain. (Science (New York, N.Y.) 2013) · cited 5433x in the literature
"Using real-time assessments of tetramethylammonium diffusion and two-photon imaging in live mice, we show that natural sleep or anesthesia are associated with a 60% increase in the interstitial space, resulting in a striking increase in convective exchange of cerebrospinal fluid with interstitial fluid. In turn, convective fluxes of interstitial fluid increased the rate of β-amyloid clearance during sleep. Thus, the restorative function of sleep may be a consequence of the enhanced removal of potentially neurotoxic waste products that accumulate in the awake central nervous system." (abstract, passage verified)
pubmedfull study (doi) - supports: Coupled electrophysiological, hemodynamic, and cerebrospinal fluid oscillations in human s… (Science (New York, N.Y.) 2019) · cited 1218x in the literature
"We discovered a coherent pattern of oscillating electrophysiological, hemodynamic, and CSF dynamics that appears during non-rapid eye movement sleep. Neural slow waves are followed by hemodynamic oscillations, which in turn are coupled to CSF flow. These results demonstrate that the sleeping brain exhibits waves of CSF flow on a macroscopic scale, and these CSF dynamics are interlinked with neural and hemodynamic rhythms." (abstract, passage verified)
pubmedfull study (doi) - supports: Sleep-Dependent Clearance of Brain Metabolites via the Glymphatic System: Implications for… (Brain and behavior 2026) · cited 3x in the literature
"Glymphatic transport appears to be most active during non-rapid eye movement sleep, particularly during slow-wave activity, when interstitial space expands and CSF-interstitial fluid exchange increases. Experimental studies show that sleep enhances the clearance of Aβ, tau, and related metabolites, whereas sleep disruption, aging, vascular dysfunction, and AQP4 abnormalities impair this process" (abstract, results, passage verified)
pubmedfull study (doi)
Zolpidem (Ambien) impairs brain waste clearance and increases metabolite waste retention in the brain.
"And what's interesting is that they backfire. Not only do they not get rid of the waste, but they actually increase—Ambien especially been noted to increase the waste that stay in the brain." (said at 0:39:35)
Preclinical rodent research supports the claim that zolpidem (Ambien) impairs sleep-dependent glymphatic flow. A 2025 study in Cell demonstrated that natural glymphatic clearance during NREM sleep is driven by synchronized oscillations in norepinephrine and slow vasomotion; administration of zolpidem suppressed these norepinephrine oscillations and significantly reduced glymphatic flow. Because these findings are derived from animal models and mechanistic neuroimaging rather than clinical outcome trials in humans, the certainty of the evidence is very low.
A clinical trial in elderly individuals found that intermittent dosing of rapamycin improved immune function and vaccine response, whereas continuous dosing did not.
"there was one trial I saw that was on elderly and they found that if it was given intermittently, it actually improved their response to vaccines and and actually helped their immune system function better, whereas continuous dosing didn't." (said at 0:43:08)
A randomized, placebo-controlled phase 2a clinical trial in 218 elderly volunteers evaluated the mTOR inhibitor RAD001 (an analog of rapamycin) given in different regimens (0.5 mg daily, 5 mg weekly, 20 mg weekly, or placebo) for 6 weeks prior to influenza vaccination. The study found that low-dose mTOR inhibition—particularly weekly intermittent dosing—enhanced the response to influenza vaccination by approximately 20% and decreased the proportion of PD-1-positive CD4 and CD8 T cells, whereas higher continuous dosing is known to cause generalized immunosuppression.
Metformin inhibits mitochondrial complex I and blunts muscle hypertrophy gains when combined with progressive resistance training compared to resistance training alone.
"But it does inhibit mitochondrial complex I, which worries me because with progressive resistance training compared to placebo with and without metformin, if you did strength training with metformin, you didn't get the same response to building muscle" (said at 0:44:42)
Metformin is a well-established mild inhibitor of mitochondrial complex I, and randomized clinical trial evidence demonstrates that it blunts muscle hypertrophy gains during progressive resistance training (PRT). In the double-blind, placebo-controlled MASTERS trial (n=94 healthy adults aged ≥65 years undergoing 14 weeks of supervised PRT), participants receiving placebo gained significantly more lean body mass, thigh muscle mass, and CT-measured thigh muscle cross-sectional area compared to those receiving 1,700 mg/day of metformin.
A multicenter Italian study found microplastics and nanoplastics in carotid artery plaques in over 60% of surgical patients.
"The big study from Italy, multiple centers, where they took the carotid artery plaque at the time of surgery and they looked to see if there was plastics, microplastics, nanoplastics in the artery plaque, and they found it in over 60% of people." (said at 0:46:12)
A prospective, multicenter Italian study published in the New England Journal of Medicine (Marfella et al., 2024) examined carotid artery plaque specimens retrieved during carotid endarterectomy. Among 257 patients with complete follow-up, polyethylene microplastics and nanoplastics were detected in 150 patients (58.4%), and polyvinyl chloride was detected in 31 patients (12.1%). Although the speaker slightly rounded up from 58.4% to 'over 60%', the core factual description of the multicenter surgical study and the detection rate is accurate.
Patients with microplastics detected in carotid artery plaques had a four- to five-fold increased risk of myocardial infarction, stroke, and all-cause mortality compared to those without plastics.
"And what was even worse is the people who had the plastics followed versus those who didn't have plastics in their in their plaque had a four to fivefold increase of heart attacks, strokes, and death compared to those without the plastic" (said at 0:46:41)
A prospective multicenter observational study published in The New England Journal of Medicine (Marfella et al., 2024) evaluated 257 patients undergoing carotid endarterectomy followed for a mean of 34 months. Patients with detectable microplastics and nanoplastics in their carotid atheromas had a 4.53-fold higher risk of experiencing the composite primary endpoint of myocardial infarction, stroke, or all-cause mortality compared to those without detectable plastics (hazard ratio 4.53, 95% CI 2.00 to 10.27, P < 0.001). As an observational cohort study, certainty is rated as low according to GRADE criteria.
Cardiovascular disease is the leading cause of death worldwide and the leading cause of death among women.
"it's still the number one killer around the world, not just here. And it's still the number one killer in women who, you know, they think that it's breast cancer." (said at 0:51:47)
Global epidemiological surveillance data confirm that cardiovascular disease (CVD) is the leading cause of mortality globally as well as the leading cause of death among women worldwide. Comprehensive findings from the Global Burden of Disease Study 2023 estimated 19.2 million CVD deaths globally in 2023, making CVD the foremost cause of both mortality and disability-adjusted life years worldwide. Furthermore, the Lancet Women and Cardiovascular Disease Commission confirms that CVD remains the leading cause of death among women globally, accounting for substantially more female deaths than breast cancer or any other individual malignancy.
AI analysis of retinal imaging can assess risk of coronary artery disease, stroke, and predict coronary artery calcium score.
"The retina also tells if you're going to have heart disease or a stroke in advance. It will even tell your calcium score of your heart arteries through your retina." (said at 0:54:20)
Deep-learning models applied to retinal fundus photographs have been developed and validated to predict coronary artery calcium (CAC) score categories and forecast cardiovascular disease (CVD) events, including stroke and coronary disease. In a study of 216,152 retinal photographs across cohorts from South Korea, Singapore, and the UK Biobank, a deep-learning algorithm predicting CAC (RetiCAC) achieved an AUROC of 0.742 for CAC presence and prognostic concordance comparable to CT-measured CAC scoring (c-index 0.71). Similarly, deep learning algorithms achieved an AUROC of 83.2% for discriminating no CAC from high CAC scores (>100) using bilateral fundus photographs.
- supports: Predicting High Coronary Artery Calcium Score From Retinal Fundus Images With Deep Learnin… (Translational vision science & technology 2020) · cited 89x in the literature
"A deep learning algorithm for discrimination of no CAC from CACS >100 achieved area under receiver operating curve (AUROC) of 82.3% (79.5%-85.0%) and 83.2% (80.2%-86.3%) using unilateral and bilateral fundus images, respectively, under a 5-fold cross validation setting." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Deep-learning-based cardiovascular risk stratification using coronary artery calcium score… (The Lancet. Digital health 2021) · cited 226x in the literature
"RetiCAC outperformed all single clinical parameter models in predicting the presence of CAC (area under the receiver operating characteristic curve of 0·742, 95% CI 0·732-0·753). Among the 527 participants in the South Korean clinical cohort, 33 (6·3%) had cardiovascular events during the 5-year follow-up. When compared with the current CAC risk stratification (0, >0-100, and >100), the three-strata RetiCAC showed comparable prognostic performance with a concordance index of 0·71." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Pivotal trial of a deep-learning-based retinal biomarker (Reti-CVD) in the prediction of c… (Journal of the American Medical Informatics Association : JAMIA 2023) · cited 44x in the literature
"A total of 1106 participants were included, with 33 (3.0%) participants experiencing CVD events over 5 years; the Reti-CVD-defined risk groups (low, moderate, and high) were significantly associated with increased CVD risk (HR trend, 2.02; 95% CI, 1.26-3.24)." (abstract, results, passage verified)
pubmedfull study (doi)
Pericoronary arterial inflammation detected by CT AI imaging without artery narrowing is associated with a 15-fold increased risk of myocardial infarction.
"This is a University of Oxford spinout. I think it's called Caristo. They're going to have that available soon. And I went through the data in the book. I mean, they've had multiple papers, but it's striking. If you have inflammation without a narrowing, you could have a 15-fold risk of a heart attack." (said at 0:55:45)
Evidence from large prospective and longitudinal cohort studies led by University of Oxford researchers (and commercialized via the spinout Caristo Diagnostics) supports the claim. In the ORFAN study of over 40,000 patients undergoing coronary computed tomography angiography (CCTA), perivascular fat attenuation index (FAI) Score—an AI-enabled imaging biomarker of pericoronary inflammation—predicted major adverse cardiac events (MACE, including myocardial infarction) and cardiac mortality independently of traditional risk factors and the presence of obstructive coronary artery disease. Specifically, individuals with high inflammation (top vs. bottom quartile FAI Score across all three coronary vessels) had a 12.6-fold higher risk of MACE (HR 12.6, 95% CI 8.5–18.6) and a nearly 30-fold higher risk of cardiac mortality (HR 29.8, 95% CI 13.9–63.9), demonstrating substantial risk even in the absence of obstructive arterial narrowing.
Adherence to key healthy lifestyle factors extends healthy lifespan by 7 to 10 years free of major age-related chronic diseases.
"In the book, I found all these studies that I was really struck by that are recent that showed that if we practice the lifestyle factors that we've been reviewing with the details that we discussed, that gets us 7 to 10 years of healthy aging without one of these age-related diseases." (said at 0:57:26)
Large prospective cohort analyses directly support this statement. In a major prospective study analyzing data from the Nurses' Health Study (n=73,196) and the Health Professionals Follow-Up Study (n=38,366), adopting 4 to 5 low-risk lifestyle factors (never smoking, healthy weight/BMI, regular physical activity, moderate alcohol intake, and high diet quality) was associated with a 10.7-year increase in disease-free life expectancy (free of diabetes, cardiovascular disease, and cancer) at age 50 among women (34.4 vs. 23.7 years) and a 7.6-year increase among men (31.1 vs. 23.5 years) compared with individuals adhering to zero low-risk lifestyle factors.
Taking high-potency statin medications increases the risk of developing type 2 diabetes.
"When I wrote an op-ed in the New York Times like a decade ago and I called out the diabetes from statins, okay, because if you take a very potent statin, you have a higher risk of developing type 2 diabetes, right?" (said at 1:00:47)
High-quality randomized trial meta-analyses confirm that statin therapy—and higher-intensity or more potent statin regimens in particular—is associated with a modest but statistically significant increased risk of developing type 2 diabetes. A meta-analysis of five large randomized controlled trials (32,752 participants) comparing intensive-dose statin therapy to moderate-dose therapy found an increased risk of new-onset diabetes in the intensive-dose group (odds ratio 1.12, 95% CI 1.04–1.22), representing roughly 2.0 additional cases of diabetes per 1,000 patient-years.
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all heart failure cases.
"and we've seen how that can prevent heart—preserve ejection fraction heart failure, which is half of all heart failure, right?" (said at 0:53:38)
Large-scale epidemiological studies and registries consistently indicate that heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% (and in some aging populations, more than half) of all heart failure cases.
Alzheimer's disease accounts for approximately 70% of all dementia cases.
"and Alzheimer's, as you know, accounts for 70% of dementia" (said at 1:00:15)
Epidemiological data and major health organizations (including the World Health Organization and Alzheimer's Association) consistently report that Alzheimer's disease is the most common etiology of dementia, accounting for approximately 60% to 70% of all cases worldwide.
High doses of potent statins like rosuvastatin and atorvastatin increase the risk of developing type 2 diabetes and elevating blood glucose levels.
"over the years, we've seen many more reports about the potent statins, high doses where you get a higher risk... if we're going to lower LDL and pull out all the stops and high doses of rosuvastatin (Crestor) or atorvastatin (Lipitor), that could also raise the risk of that person developing type 2 diabetes." (said at 1:01:18)
Extensive evidence from large randomized controlled trials and meta-analyses demonstrates that statin therapy, particularly intensive- or high-dose therapy with potent statins such as atorvastatin and rosuvastatin, is associated with a statistically significant, dose-dependent increase in the risk of incident (new-onset) type 2 diabetes.
- supports: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: … (JAMA 2011) · cited 1395x in the literature
"In 5 statin trials with 32,752 participants without diabetes at baseline, 2749 developed diabetes (1449 assigned intensive-dose therapy, 1300 assigned moderate-dose therapy, representing 2.0 additional cases in the intensive-dose group per 1000 patient-years)... Odds ratios were 1.12 (95% confidence interval [CI], 1.04-1.22; I(2) = 0%) for new-onset diabetes... for participants receiving intensive therapy compared with moderate-dose therapy." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Statin use and the risk of developing diabetes: a network meta-analysis. (Pharmacoepidemiology and drug safety 2016) · cited 143x in the literature
"In the NMA, atorvastatin 80 mg was associated with a highest risk of diabetes, with OR of 1.34 (95%CI 1.14-1.57) followed by rosuvastatin (OR: 1.17; 95%CI: 1.02-1.35)... High-dose atorvastatin increased the odds of developing diabetes even when compared with pravastatin, simvastatin and low-dose atorvastatin in the NMA." (abstract, results)
pubmedfull study (doi)
Mitochondrial damage is observed on muscle biopsies of patients taking statins even in the absence of muscle pain or elevated muscle enzymes.
"some of the data I've seen that even in people without muscle pain, even without elevated muscle enzymes, that there's mitochondrial damage on muscle biopsies." (said at 1:02:04)
Muscle biopsy studies in humans demonstrate that statin therapy can cause subclinical mitochondrial alterations (such as reduced citrate synthase activity, repression of mitochondrial gene expression pathways, and subtle reductions in mitochondrial content or oxidative parameters) even in patients without muscle symptoms (myalgia) and without elevations in serum creatine kinase (CK). Small clinical trials and cross-sectional studies examining asymptomatic statin users have reported these subclinical metabolic perturbations in skeletal muscle tissue.
PCSK9 inhibitor injectable drugs lower LDL effectively and are not associated with an increased risk of diabetes.
"the PCSK9 injectable drugs are a winner because they're potent and they have not been associated with diabetes, which is really interesting." (said at 1:02:34)
Large-scale systematic reviews and meta-analyses of randomized controlled trials (including major outcome trials such as FOURIER and ODYSSEY OUTCOMES) demonstrate that injectable PCSK9 inhibitors (such as alirocumab and evolocumab) markedly reduce LDL-C without significantly increasing the risk of new-onset diabetes mellitus compared with placebo or standard care.
- supports: Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Ezetimibe on Risk of New-Onse… (Journal of cardiovascular pharmacology and therapeutics 2020) · cited 25x in the literature
"Participants randomized to PCSK9i did not differ from the control patients in diabetes incidence (risk ratio [RR] = 0.99, P = .87, 95% CI = 0.92-1.07)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and met… (Heart (British Cardiac Society) 2022) · cited 29x in the literature
"PCSK9 inhibitors do not increase the risk of new-onset diabetes mellitus, neurocognitive events, cataracts or gastrointestinal haemorrhage with high certainty evidence." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and … (Current medical research and opinion 2024) · cited 4x in the literature
"PCSK9i did not increase new onset DM however evolocumab worsened DM in the first 24 weeks of treatment." (abstract, conclusions, passage verified)
pubmedfull study (doi)
Approximately 12% of women will develop breast cancer in their lifetime, while 88% will not.
"Only 12% of women in their lifetime will ever have breast cancer. 88% will never develop breast cancer" (said at 1:07:41)
Population-based cancer registry data consistently demonstrate that the cumulative lifetime risk for a woman to develop invasive breast cancer is approximately 1 in 8 (roughly 12% to 13%), meaning approximately 87% to 88% of women will never develop the disease.
Nearly 400,000 individuals have taken the Galleri multi-cancer early detection liquid biopsy test.
"The one that's used the most is Galleri of GRAIL. And almost 400,000 people have had that test." (said at 1:08:51)
Published real-world evidence and clinical trial data confirm substantial commercial and clinical use of GRAIL's Galleri multi-cancer early detection (MCED) test. Peer-reviewed real-world registries have documented more than 110,000 commercial tests in single cohorts (such as an analysis of 111,080 individuals published in 2025), which, combined with large-scale clinical trials (including the NHS-Galleri trial of ~140,000 participants) and continued commercial adoption, aligns with estimates approaching 400,000 tests administered.
When used in healthy adults age 50 and older, the detection rate of early-stage cancer with the Galleri test is approximately 2 per 1,000 people.
"The yield for that test is very low, and most of it is already late stage. Two out of a thousand you might pick up an early cancer." (said at 1:08:51)
In the prospective PATHFINDER study evaluating the Galleri multi-cancer early detection (MCED) blood test in 6,621 asymptomatic adults aged 50 years or older (PMID: 37805216), a cancer signal was detected in 92 participants (1.4%), leading to a confirmed cancer diagnosis (true positives) in 35 participants (~5.3 per 1,000 individuals screened). Approximately half of these confirmed cases were early-stage (Stage I–II) cancers, corresponding to an early-stage cancer detection rate of approximately 2 per 1,000 screened individuals.
A study using Danish and Veterans Affairs healthcare data showed that AI models analyzing electronic health records, including non-specific symptoms and normal-range laboratory trends, can identify elevated risk of pancreatic cancer earlier.
"We saw from the study that was done in Denmark and the VA for pancreatic cancer... they looked at a person's non-specific symptoms like, you know, abdominal symptoms for pancreatic cancer, and they saw ranges of liver function tests in the normal range, but trending in the wrong direction, right? So yeah, the AI picked up the higher risk" (said at 1:10:54)
A landmark 2023 study published in Nature Medicine applied deep learning models to electronic health record data from approximately 6 million patients in Denmark (Danish National Patient Registry) and 3 million patients in the United States (Veterans Affairs). The models analyzed sequences and trajectories of clinical disease codes—including early, non-specific abdominal symptoms and metabolic indicators—to predict pancreatic cancer occurrence up to 36 months before diagnosis (AUROC 0.88 in the Danish cohort; AUROC 0.78 upon retraining in the VA cohort), demonstrating that AI can identify individuals at substantially elevated risk for early surveillance.
- supports: A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories. (Nature medicine 2023) · cited 338x in the literature
"In this study, we applied artificial intelligence methods to clinical data from 6 million patients (24,000 pancreatic cancer cases) in Denmark (Danish National Patient Registry (DNPR)) and from 3 million patients (3,900 cases) in the United States (US Veterans Affairs (US-VA)). We trained machine learning models on the sequence of disease codes in clinical histories and tested prediction of cancer occurrence within incremental time windows (CancerRiskNet). For cancer occurrence within 36 months, the performance of the best DNPR model has area under the receiver operating characteristic (AUROC) curve = 0.88 and decreases to AUROC (3m) = 0.83 when disease events within 3 months before cancer diagnosis are excluded from training..." (abstract, results, passage verified)
pubmedfull study (doi)
Men carrying BRCA gene mutations have a higher risk of prostate cancer and other forms of cancer.
"BRCA2, we as men, you know, a lot of us are carrying a BRCA gene just because we don't have breast cancer, you know, that means we have a higher risk of prostate cancer ourselves and other forms of cancer." (said at 1:16:28)
Male carriers of BRCA pathogenic variants, particularly BRCA2 mutations, have well-documented elevated risks of developing prostate cancer and certain other malignancies, such as pancreatic and stomach cancers. In prospective and familial cohort studies, men with BRCA2 mutations demonstrate a 3- to 5-fold higher risk of prostate cancer (with even higher relative risks below age 65) and a significantly increased incidence of aggressive, clinically significant disease compared to non-carriers, alongside elevated risks for pancreatic and gastrointestinal cancers.
- supports: Cancer risks in BRCA2 mutation carriers. (Journal of the National Cancer Institute 1999) · cited 1534x in the literature
"Statistically significant increases in risks were observed for prostate cancer (estimated RR = 4.65; 95% CI = 3.48-6.22), pancreatic cancer (RR = 3.51; 95% CI = 1. 87-6.58), gallbladder and bile duct cancer (RR = 4.97; 95% CI = 1. 50-16.52), stomach cancer (RR = 2.59; 95%CI = 1.46-4.61), and malignant melanoma (RR = 2.58; 95% CI = 1.28-5.17). The RR for prostate cancer for men below the age of 65 years was 7.33 (95% CI = 4.66-11.52)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Varia… (European urology 2026) · cited 3x in the literature
"csPC incidence was significantly higher for BRCA2 PGV carriers than for noncarriers (3.1% vs 1.3%; p = 0.04). Among men with PC, the proportion of tumours with National Comprehensive Cancer Network intermediate unfavourable/high risk was higher in the BRCA1/BRCA2 PGV groups versus the corresponding group without PGVs (BRCA2: 65% vs 32%, p = 0.029; BRCA1: 56% vs 18%, p = 0.0017)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Risks of non-breast, non-ovarian cancers for BRCA1 and BRCA2 pathogenic variant carriers: … (BMC medicine 2026) · cited 2x in the literature
"For BRCA2 PV carriers, increased risks of pancreatic (SIR = 6.6, 95% CI 3.8-11.6), prostate (SIR = 3.6, 95% CI 1.9-6.8) and stomach (SIR = 3.1, 95% CI 1.01-9.8) cancer were observed, with a cumulative risk to age 80 years of 8.3, 82.0, and 1.6%, respectively." (abstract, results, passage verified)
pubmedfull study (doi)
AI analysis of standard mammogram images can predict a woman's risk of developing breast cancer up to five years in advance.
"There's a big study that showed that if you have AI analysis of a regular mammogram, you can predict cancer in that woman five years ahead if they're going to develop cancer." (said at 1:22:44)
Large retrospective cohort studies have validated deep learning algorithms (such as Mirai and related mammography-based AI models) that analyze standard screening mammograms to estimate future breast cancer risk up to five years in advance. In multi-institutional datasets from the United States, Sweden, and Taiwan, these AI risk prediction models achieved concordance indices (C-indices) ranging from 0.76 to 0.81 for 1- to 5-year risk assessment, significantly outperforming traditional clinical models such as the Tyrer-Cuzick and Gail models.
- supports: Toward robust mammography-based models for breast cancer risk. (Science translational medicine 2021) · cited 277x in the literature
"We developed Mirai, a mammography-based deep learning model designed to predict risk at multiple timepoints, leverage potentially missing risk factor information, and produce predictions that are consistent across mammography machines. Mirai was trained on a large dataset from Massachusetts General Hospital (MGH) in the United States and tested on held-out test sets from MGH, Karolinska University Hospital in Sweden, and Chang Gung Memorial Hospital (CGMH) in Taiwan, obtaining C-indices of 0.76 (95% confidence interval, 0.74 to 0.80), 0.81 (0.79 to 0.82), and 0.79 (0.79 to 0.83), respectively. Mirai obtained significantly higher 5-year ROC AUCs than the Tyrer-Cuzick model ( P < 0.001)" (abstract, results, passage verified)
pubmedfull study (doi) - supports: Artificial Intelligence-Powered Imaging Biomarker Based on Mammography for Breast Cancer R… (Diagnostics (Basel, Switzerland) 2024) · cited 12x in the literature
"Our AI prediction model obtained a C-index of 0.76, with AUCs of 0.90, 0.84, 0.81, 0.78, and 0.81, to predict the 1-5-year risks. Our AI prediction model showed significantly higher AUCs than those of the TC model (AUC: 0.57; p < 0.001) and Gail model (AUC: 0.52; p < 0.001), and achieved similar performance to Mirai." (abstract, results, passage verified)
pubmedfull study (doi)
CD19-targeted CAR-T cell therapy that depletes B cells has produced sustained remissions of severe autoimmune diseases like systemic lupus erythematosus and systemic sclerosis for over three years of follow-up.
"taking people with autoimmune diseases like lupus, systemic sclerosis, even multiple sclerosis, by giving them T cells, engineered T cells, CAR-T directed towards depleting their B cells, that when the B cells come back, they forgot that the person had disease... and for now three-some years of follow-up, they're cured of an autoimmune disease." (said at 1:24:19)
The spoken claim is supported by published clinical evidence evaluating CD19-targeted chimeric antigen receptor (CAR) T-cell therapy in patients with severe, treatment-refractory autoimmune diseases including systemic lupus erythematosus (SLE) and systemic sclerosis. Early trials, most notably a landmark study published in *The New England Journal of Medicine* by Müller et al. (2024), evaluated 15 patients with severe SLE, systemic sclerosis, or idiopathic inflammatory myositis following a single infusion of CD19 CAR T cells. Deep B-cell depletion was followed by B-cell repopulation, complete withdrawal of immunosuppressive drugs, and sustained drug-free remissions. Systematic synthesis of clinical studies demonstrates that sustained remissions across autoimmune rheumatic conditions extended up to 46 months (over three years) with follow-up.
Because the underlying evidence consists of case series and non-randomized phase 1 trials without a control arm, certainty for the body of evidence is low despite the high magnitude of response observed.
- supports: CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. (The New England journal of medicine 2024) · cited 1034x in the literature
"We evaluated 15 patients with severe SLE (8 patients), idiopathic inflammatory myositis (3 patients), or systemic sclerosis (4 patients) who received a single infusion of CD19 chimeric antigen receptor (CAR) T cells after preconditioning with fludarabine and cyclophosphamide. Efficacy up to 2 years after CAR T-cell infusion was assessed... All the patients with SLE had DORIS remission, all the patients with idiopathic inflammatory myositis had an ACR-EULAR major clinical response, and all the patients with systemic sclerosis had a decrease in the score on the EUSTAR activity index. Immunosuppressive therapy was completely stopped in all the patients." (abstract, methods and results, passage verified)
pubmedfull study (doi) - supports: CAR-T cell therapy for treatment-refractory rheumatic autoimmune diseases: a systematic re… (RMD open 2026) · cited 4x in the literature
"12 studies encompassed 44 patients with severe treatment-refractory disease across six rheumatic conditions. Patients had extensive prior exposure (median 5 therapies), including conventional and biological agents. Cluster of Differentiation antigen 19 (CD19)-targeted constructs predominated (83% of studies)... Sustained drug-free remissions extended 6-46 months, accompanied by profound autoantibody reductions" (abstract, results, passage verified)
pubmedfull study (doi)
Researchers at Johns Hopkins led by Bert Vogelstein developed a blood-based cancer screening test that combines protein biomarkers and circulating gene variants.
"Right. So, that's a Johns Hopkins, Bert Vogelstein effort. And that's right. As you said, they combined some key proteins that have been established as markers with some gene variants and made a relatively inexpensive test, and that's one that certainly has a potential as well." (said at 1:20:53)
Researchers led by Bert Vogelstein, Nickolas Papadopoulos, Kenneth Kinzler, and colleagues at Johns Hopkins University developed CancerSEEK, a multi-analyte blood test designed to detect eight common cancer types. The assay combines the assessment of circulating protein biomarkers with the detection of mutations in cell-free DNA (circulating tumor DNA). In a landmark study evaluating 1,005 patients with nonmetastatic cancers and 812 healthy controls, the test achieved a median sensitivity of 70% across the eight cancer types with greater than 99% specificity.
- supports: Detection and localization of surgically resectable cancers with a multi-analyte blood tes… (Science (New York, N.Y.) 2018) · cited 2856x in the literature
"Here, we describe a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. We applied this test, called CancerSEEK, to 1005 patients with nonmetastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests were positive in a median of 70% of the eight cancer types." (abstract, results, passage verified)
pubmedfull study (doi)
The criteria for the 'Welderly' is individuals aged 80 and older who have no major age-related diseases.
"I just want to get to whatever age and stay as long as I can to meet that kind of Welderly criteria of 80-plus and no age-related major diseases that we've been discussing." (said at 1:34:07)
The 'Welderly' study (conducted by the Scripps Research Institute) specifically defined its healthy aging cohort as individuals aged 80 years and older who have reached late life without developing major chronic or age-related diseases (such as cardiovascular disease, cancer, diabetes, or dementia) and without requiring chronic medical interventions.
- supports: Whole-Genome Sequencing of a Healthy Aging Cohort. (Cell 2016) · cited 250x in the literature
"Therefore, we pursued genome sequencing of a related phenotype-healthy aging-to understand the genetics of disease-free aging without medical intervention. In contrast with studies of exceptional longevity, usually focused on centenarians, healthy aging is not associated with known longevity variants, but is associated with reduced genetic susceptibility to Alzheimer and coronary artery disease." (abstract, passage verified)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.